Clinical Trial Update: Efficacy and Safety of Beta-adrenoceptor Inverse Agonist, Nadolol, in Mild Asthma [Phase 2]

View source ↗

Summary

Phase 2 trial results evaluating the efficacy and safety of Nadolol, a beta-adrenoceptor inverse agonist, in patients with mild asthma; study sponsored by Invio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Nadolol (Nadolol)

Snippet

Sponsor: Invion, Inc. | Conditions: Mild Persistent Asthma, Uncomplicated | Phase 2 | Status: UNKNOWN